Quarterly report pursuant to Section 13 or 15(d)

Segment, Geographical and Other Revenue Information - Segment Reporting (Details)

v3.20.1
Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Segment Reporting Information [Line Items]    
Total revenues $ 14,670 $ 15,583
Cost of product revenue 2,541 4,391
Research and development 10,967 8,016
Selling, general and administrative 8,989 8,415
Total costs and operating expenses 22,497 20,822
Income (loss) from operations (7,827) (5,239)
Depreciation and amortization (438) (319)
Income (loss) before income taxes (7,647) (5,133)
Stock-based compensation 2,169 2,063
Performance Enzymes [Member]    
Segment Reporting Information [Line Items]    
Total revenues 10,874 10,087
Novel Biotherapeutics [Member]    
Segment Reporting Information [Line Items]    
Total revenues 3,796 5,496
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Total revenues 14,670 15,583
Cost of product revenue 2,541 4,391
Research and development 10,621 7,759
Selling, general and administrative 2,936 2,618
Total costs and operating expenses 16,098 14,768
Income (loss) from operations (1,428) 815
Income (loss) before income taxes (7,647) (5,133)
Stock-based compensation 2,169 2,063
Operating Segments [Member] | Performance Enzymes [Member]    
Segment Reporting Information [Line Items]    
Total revenues 10,874 10,087
Cost of product revenue 2,541 4,391
Research and development 5,696 4,442
Selling, general and administrative 2,345 2,101
Total costs and operating expenses 10,582 10,934
Income (loss) from operations 292 (847)
Stock-based compensation 756 636
Operating Segments [Member] | Novel Biotherapeutics [Member]    
Segment Reporting Information [Line Items]    
Total revenues 3,796 5,496
Research and development 4,925 3,317
Selling, general and administrative 591 517
Total costs and operating expenses 5,516 3,834
Income (loss) from operations (1,720) 1,662
Stock-based compensation 241 141
Corporate [Member]    
Segment Reporting Information [Line Items]    
Total costs and operating expenses (5,727) (5,575)
Depreciation and amortization (492) (373)
Stock-based compensation 1,172 1,286
Product Sales [Member]    
Segment Reporting Information [Line Items]    
Total revenues 5,100 7,988
Product Sales [Member] | Performance Enzymes [Member]    
Segment Reporting Information [Line Items]    
Total revenues 5,100 7,988
Product Sales [Member] | Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Total revenues 5,100 7,988
Product Sales [Member] | Operating Segments [Member] | Performance Enzymes [Member]    
Segment Reporting Information [Line Items]    
Total revenues 5,100 7,988
Research and Development Revenue [Member]    
Segment Reporting Information [Line Items]    
Total revenues 9,570 7,595
Research and Development Revenue [Member] | Performance Enzymes [Member]    
Segment Reporting Information [Line Items]    
Total revenues 5,774 2,099
Research and Development Revenue [Member] | Novel Biotherapeutics [Member]    
Segment Reporting Information [Line Items]    
Total revenues 3,796 5,496
Research and Development Revenue [Member] | Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Total revenues 9,570 7,595
Research and Development Revenue [Member] | Operating Segments [Member] | Performance Enzymes [Member]    
Segment Reporting Information [Line Items]    
Total revenues 5,774 2,099
Research and Development Revenue [Member] | Operating Segments [Member] | Novel Biotherapeutics [Member]    
Segment Reporting Information [Line Items]    
Total revenues $ 3,796 $ 5,496